Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

A Thorough QT/QTc Study of Clobazam in Healthy Volunteers.

Tolbert D, Gordon J, Harris S, Walzer M, Bekersky I, Reid S.

Clin Ther. 2017 Oct;39(10):2073-2086. doi: 10.1016/j.clinthera.2017.08.020. Epub 2017 Sep 27.

PMID:
28958437
2.

Vigabatrin Lacks Proarrhythmic Potential: Results from a Thorough QT/QTc Study in Healthy Volunteers.

Tolbert D, Reid S, Harris S, Bekersky I.

Clin Ther. 2017 Aug;39(8):1639-1648. doi: 10.1016/j.clinthera.2017.06.006. Epub 2017 Jun 28.

3.

Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.

Seibel NL, Shad AT, Bekersky I, Groll AH, Gonzalez C, Wood LV, Jarosinski P, Buell D, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01477-16. doi: 10.1128/AAC.01477-16. Print 2017 Feb.

4.

Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions.

Tolbert D, Bekersky I, Chu HM, Ette EI.

J Clin Pharmacol. 2016 Mar;56(3):365-74. doi: 10.1002/jcph.603. Epub 2015 Sep 29.

PMID:
26224203
5.

An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics.

Tolbert D, Bekersky I, Chu HM, Ette EI.

J Clin Pharmacol. 2016 Feb;56(2):213-22. doi: 10.1002/jcph.586. Epub 2015 Sep 7.

PMID:
26139309
6.

Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy.

Tolbert D, Cloyd J, Biton V, Bekersky I, Walzer M, Wesche D, Drummond R, Lee D.

Epilepsia. 2015 Jun;56(6):915-23. doi: 10.1111/epi.13012. Epub 2015 May 16.

7.

Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials.

Lee D, Kalu U, Halford JJ, Biton V, Cloyd J, Klein P, Bekersky I, Peng G, Dheerendra S, Tolbert D.

Epilepsia. 2015 Jun;56(6):906-14. doi: 10.1111/epi.12991. Epub 2015 Apr 25.

8.

Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome.

Tolbert D, Harris SI, Bekersky I, Lee D, Isojarvi J.

Epilepsy Behav. 2014 Aug;37:11-5. doi: 10.1016/j.yebeh.2014.05.016. Epub 2014 Jun 18.

9.

Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.

Walzer M, Bekersky I, Blum RA, Tolbert D.

Pharmacotherapy. 2012 Apr;32(4):340-53. doi: 10.1002/j.1875-9114.2012.01028.x. Epub 2012 Mar 15.

PMID:
22422635
10.

Oral toxicity of vigabatrin in immature rats: characterization of intramyelinic edema.

Walzer M, Bekersky I, Wanaski S, Collins S, Jortner B, Patterson R, Garman R, Sagar S, Tolbert D.

Neurotoxicology. 2011 Dec;32(6):963-74. doi: 10.1016/j.neuro.2011.03.014. Epub 2011 Apr 5.

PMID:
21473881
11.

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.

Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I.

J Clin Pharmacol. 2005 Oct;45(10):1145-52.

PMID:
16172179
12.

Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.

Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, Bekersky I.

J Clin Pharmacol. 2005 Sep;45(9):1018-24.

PMID:
16100295
13.

Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers.

Hebert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D, Keirns J, Bekersky I.

J Clin Pharmacol. 2005 Aug;45(8):954-60.

PMID:
16027407
14.

Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat.

Bilolo KK, Ouyang J, Wang X, Zhu S, Jiang W, Qi S, Xu D, Hebert MJ, Bekersky I, Fitzsimmons WE, Chen H.

Transplantation. 2003 Jun 15;75(11):1881-7.

PMID:
12811249
15.

Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts.

Vu MD, Qi S, Wang X, Jiang W, Ma A, Xu D, Bekersky I, Fitzsimmons WE, Wu J, Chen H.

Transplantation. 2003 May 15;75(9):1455-9.

PMID:
12792496
16.

Significant prolongation of renal allograft survival by delayed combination therapy of FK778 with tacrolimus in nonhuman primates.

Qi S, Zhu S, Xu D, Wang X, Ouyang J, Jiang W, Vu MD, Bilolo K, Ma A, Johnson S, Daloze P, Bekersky I, Fitzsimmons WE, Chen H.

Transplantation. 2003 Apr 27;75(8):1124-8.

PMID:
12717189
17.

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.

Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hemmings M, Lyman CA, Sein T, Bacher J, Bekersky I, Walsh TJ.

Antimicrob Agents Chemother. 2002 Jun;46(6):1857-69.

19.

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ.

Antimicrob Agents Chemother. 2002 Mar;46(3):828-33.

20.

Tacrolimus pharmacology and nonclinical studies: from FK506 to protopic.

Bekersky I, Lilja H, Lawrence I.

Semin Cutan Med Surg. 2001 Dec;20(4):226-32. Review.

PMID:
11770909
21.

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ.

Antimicrob Agents Chemother. 2001 Dec;45(12):3487-96.

22.

Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.

Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Piscitelli SC, Bekersky I, Walsh TJ.

Antimicrob Agents Chemother. 2001 Dec;45(12):3322-7.

23.

Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers.

Bekersky I, Fielding RM, Dressler DE, Kline S, Buell DN, Walsh TJ.

J Clin Pharmacol. 2001 Sep;41(9):963-71.

PMID:
11549101
24.

Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects.

Bekersky I, Dressler D, Alak A, Boswell GW, Mekki QA.

J Clin Pharmacol. 2001 Jun;41(6):628-35.

PMID:
11402631
25.

Quantitation of free and total amphotericin B in human biologic matrices by a liquid chromatography tandem mass spectrometric method.

Lee JW, Petersen ME, Lin P, Dressler D, Bekersky I.

Ther Drug Monit. 2001 Jun;23(3):268-76.

PMID:
11360037
26.

Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats.

Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ.

Pharm Res. 2000 Dec;17(12):1494-502.

PMID:
11303959
27.

Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats.

Townsend RW, Zutshi A, Bekersky I.

Drug Metab Dispos. 2001 May;29(5):681-5.

PMID:
11302934
28.

Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose.

Bekersky I, Dressler D, Mekki Q.

J Clin Pharmacol. 2001 Mar;41(3):289-97.

PMID:
11269569
29.
30.

The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups.

Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, Christians U.

Clin Pharmacol Ther. 2001 Jan;69(1):24-31.

PMID:
11180035
31.

Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis.

Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I.

J Am Acad Dermatol. 2001 Jan;44(1 Suppl):S17-27. Review.

PMID:
11145792
32.

Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus.

Chen H, Peng J, Luo H, Loubeau M, Wan X, Xu D, Qi S, Vu MD, Daloze P, Fitzsimmons WE, Bekersky I, Peets J, Sehgal SN, Wu J.

Transplantation. 2000 Apr 27;69(8):1555-61.

PMID:
10836361
33.

Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability.

Pirsch J, Bekersky I, Vincenti F, Boswell G, Woodle ES, Alak A, Kruelle M, Fass N, Facklam D, Mekki Q.

J Clin Pharmacol. 2000 May;40(5):527-32.

PMID:
10806606
34.

Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey.

Qi S, Xu D, Peng J, Vu MD, Wu J, Bekersky I, Fitzsimmons WE, Peets J, Sehgal S, Daloze P, Chen H.

Transplantation. 2000 Apr 15;69(7):1275-83.

PMID:
10798741
35.

Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg.

Bekersky I, Dressler D, Mekki QA.

Clin Ther. 1999 Dec;21(12):2058-64.

PMID:
10645753
36.

Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs.

Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ.

Pharm Res. 1999 Nov;16(11):1694-701.

PMID:
10571274
37.

Bioequivalence of 1 and 5 mg tacrolimus capsules using a replicate study design.

Bekersky I, Dressler D, Colburn W, Mekki Q.

J Clin Pharmacol. 1999 Oct;39(10):1032-7.

PMID:
10516937
38.

Lipid-based amphotericin B formulations: from animals to man.

Bekersky I I, Fielding RM, Buell D, Lawrence I I.

Pharm Sci Technolo Today. 1999 Jun;2(6):230-236.

PMID:
10366838
39.

Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers.

Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I.

J Clin Pharmacol. 1999 Jan;39(1):91-6.

PMID:
9987705
40.

Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse.

Chen H, Qi S, Xu D, Fitzsimmons WE, Bekersky I, Sehgal SN, Daloze P.

Transplant Proc. 1998 Sep;30(6):2579-81. No abstract available.

PMID:
9745497
41.

Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.

Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J, Wilson W.

Antimicrob Agents Chemother. 1998 Sep;42(9):2391-8.

42.

AmBisome (liposomal amphotericin B): a comparative review.

Boswell GW, Buell D, Bekersky I.

J Clin Pharmacol. 1998 Jul;38(7):583-92. Review. Erratum in: J Clin Pharmacol 1999 Apr;39(4):428.

PMID:
9702842
43.

Bioequivalence of a new strength tacrolimus capsule under development.

Bekersky I, Dressler D, Boswell GW, Fergen B, Tracewell W, Mekki Q.

Transplant Proc. 1998 Jun;30(4):1457-9. No abstract available.

PMID:
9636591
44.

Demographic considerations in tacrolimus pharmacokinetics.

Fitzsimmons WE, Bekersky I, Dressler D, Raye K, Hodosh E, Mekki Q.

Transplant Proc. 1998 Jun;30(4):1359-64. No abstract available.

PMID:
9636552
45.

FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse.

Chen H, Qi S, Xu D, Vu DM, Fitzsimmons WE, Bekersky I, Peets J, Sehgal SN, Daloze P.

Transplant Proc. 1998 Jun;30(4):1039-41. No abstract available.

PMID:
9636419
46.

Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.

Boswell GW, Bekersky I, Buell D, Hiles R, Walsh TJ.

Antimicrob Agents Chemother. 1998 Feb;42(2):263-8.

47.

Tacrolimus pharmacokinetics in BMT patients.

Boswell GW, Bekersky I, Fay J, Wingard J, Antin J, Weisdorf D, Maher R, Fitzsimmons W, Nash R.

Bone Marrow Transplant. 1998 Jan;21(1):23-8.

48.

Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children.

Alaiti S, Kang S, Fiedler VC, Ellis CN, Spurlin DV, Fader D, Ulyanov G, Gadgil SD, Tanase A, Lawrence I, Scotellaro P, Raye K, Bekersky I.

J Am Acad Dermatol. 1998 Jan;38(1):69-76.

PMID:
9448208
49.

Plasma concentrations and disposition of clonidine following a constant 14-day epidural infusion in cancer patients.

Boswell G, Bekersky I, Mekki Q, Eisenach J.

Clin Ther. 1997 Sep-Oct;19(5):1024-30.

PMID:
9385489
50.

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole.

Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF.

Clin Pharmacol Ther. 1997 Jul;62(1):41-9.

PMID:
9246018

Supplemental Content

Loading ...
Support Center